Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06089954 · ClinicalTrials.gov registry record · NA
Penn Medicine Biobank Return of Results Program
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 2,500
- Enrollment target
NCT06089954 is a NA study that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 2,500 participants.
The verdict
NCT06089954, a NA study, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 2,500 participants
- Enrollment target
Study Summary
The goal of this hybrid type 1 effectiveness-implementation study is to evaluate and compare different ways of delivering genetic research results to participants. The main questions the study aims to answer are: * Is sharing actionable genetic research results with participants through a multimedia patient-informed eHealth intervention (e.g. patient portal) no worse than sharing results by telephone or videoconference with a genetic counselor? * Will research participants access an eHealth educational intervention or chatbot education to learn about research results being offered and the option to decline learning their individual research results and how frequently participants choose to decline actionable research results? * Who benefits less and more from digital intervention with return of actionable research results and what barriers exist to using these tools for return of research results outside this study? Participants in the biobank will be offered digital tools to learn about research results being offered and the option to decline receiving these results. Those who don't decline and have an actionable result will be randomly assigned to receive their results with a genetic counselor or through an eHealth portal. Participants will complete surveys before and after receipt of results to understand patient experiences with these methods of education and return of results to determine if digital tools can be used to help ensure more patients get access to research results which could impact their health.
Interventions
- OTHER private web-portal eHealth disclosure of genetic results
- OTHER eHealth education intervention (web or chatbot)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06089954
The ClinicalTrials.gov registry entry for NCT06089954 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which private web-portal eHealth disclosure of genetic results is the first listed.
NCT06089954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06089954 about?
NCT06089954 is a clinical study titled "Penn Medicine Biobank Return of Results Program". The goal of this hybrid type 1 effectiveness-implementation study is to evaluate and compare different ways of delivering genetic research results to participants. The main questions the study aims to answer are: * Is sharing actionable genetic research results with participants through a multimedi...
What is the current status of trial NCT06089954?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2023-10-20. Estimated completion is 2026-09-30.
What interventions are being tested in trial NCT06089954?
The interventions under investigation include: private web-portal eHealth disclosure of genetic results (OTHER), eHealth education intervention (web or chatbot) (OTHER).
Who is sponsoring clinical trial NCT06089954?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.